![Jaakko Lappalainen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jaakko Lappalainen is a former Executive Director of Drug Development Services at Premier Research Group Ltd., former Vice President of Clinical Development at Marinus Pharmaceuticals, Inc., former Senior Vice President of Clinical Development and Pharmacovigilance at VistaGen Therapeutics, Inc. from 2021 to 2023, and a former Assistant Professor at Yale School of Medicine.
| Companies | Position | End |
|---|---|---|
| VISTAGEN THERAPEUTICS, INC. | Corporate Officer/Principal | 2023-05-31 |
Yale School of Medicine
 Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Premier Research Group Ltd.
 Premier Research Group Ltd. Miscellaneous Commercial ServicesCommercial Services Provides contract research services to pharmaceutical industry | Corporate Officer/Principal | - |
| MARINUS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
Active
Inactive
Listed companies
Private companies
| Private companies | 4 |
|---|---|
Premier Research Group Ltd.
Premier Research Group Ltd. Miscellaneous Commercial ServicesCommercial Services Provides contract research services to pharmaceutical industry | Commercial Services |
Marinus Pharmaceuticals, Inc.
 Marinus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for rare genetic epilepsies and other seizure disorders | Health Technology |
VistaGen Therapeutics, Inc.
 VistaGen Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops central nervous system therapies | Health Technology |
Yale School of Medicine
Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Select your edition
All financial news and data tailored to specific country editions
